Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly LLY revealed 16 unusual trades.
Delving into the details, we found 56% of traders were bullish, while 43% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $155,420, and 12 were calls, valued at $1,122,660.
Projected Price Targets
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $300.0 to $630.0 for Eli Lilly during the past quarter.
Volume & Open Interest Trends
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Eli Lilly's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Eli Lilly's substantial trades, within a strike price spectrum from $300.0 to $630.0 over the preceding 30 days.
Eli Lilly Call and Put Volume: 30-Day Overview
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| LLY | CALL | TRADE | BEARISH | 02/16/24 | $590.00 | $639.0K | 530 | 307 |
| LLY | CALL | TRADE | BULLISH | 06/21/24 | $390.00 | $76.6K | 122 | 4 |
| LLY | CALL | SWEEP | NEUTRAL | 01/19/24 | $480.00 | $54.6K | 699 | 6 |
| LLY | CALL | TRADE | NEUTRAL | 06/21/24 | $580.00 | $50.4K | 548 | 10 |
| LLY | CALL | TRADE | BULLISH | 01/19/24 | $570.00 | $49.9K | 1.4K | 69 |
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
In light of the recent options history for Eli Lilly, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Where Is Eli Lilly Standing Right Now?
- Currently trading with a volume of 602,331, the LLY's price is down by -0.36%, now at $568.35.
- RSI readings suggest the stock is currently may be approaching oversold.
- Anticipated earnings release is in 37 days.
What The Experts Say On Eli Lilly
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $630.0.
- An analyst from Truist Securities has revised its rating downward to Buy, adjusting the price target to $650.
- Reflecting concerns, an analyst from Daiwa Capital lowers its rating to Outperform with a new price target of $610.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
